Ibrexafungerp
- Generic Name
- Ibrexafungerp
- Brand Names
- Brexafemme
- Drug Type
- Small Molecule
- Chemical Formula
- C44H67N5O4
- CAS Number
- 1207753-03-4
- Unique Ingredient Identifier
- A92JFM5XNU
- Background
Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals. Ibrexafungerp is orally bioavailable compared to the echinocandins caspofungin, micafungin, and anidulafungin; which can only be administered parenterally. Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity.
Ibrexafungerp was granted FDA approval on 1 June 2021.
- Indication
Ibrexafungerp is indicated in the treatment of vulvovaginal candidiasis in post-menarchal patients. It is also indicated for the reduction in the incidence of recurrent vulvovaginal candidiasis.
- Associated Conditions
- Recurrent Vulvovaginal Candidiasis, Vulvovaginal Candidiasis
- Associated Therapies
- -
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.